ANNX

Several events have impacted Annexon's stock price over the past six months. Annexon reported better-than-expected Q1 2026 results, with an EPS of $(0.23). Wall Street Zen upgraded Annexon from a "sell" to a "hold" rating. Investors are focused on a catalyst calendar for 2026, including topline Phase 3 ARCHER II data for vonaprument, a BLA submission for tanruprubart, and proof-of-concept data for ANX1502. A proposed increase in authorized common shares signals potential dilution. The company reported $225.0 million in cash, expected to fund operations into the second half of 2027. The stock's 52-week range extends from $1.60 to $7.18, with a closing price of $5.52 as of May 7, 2026.